Plasma concentrations. Trough plasma concentration (± SE)–time profiles of (A) PKC412 and its metabolites, (B) CGP62221, and (C) CGP52421 following oral doses of 75 mg PKC412 3 times a day in patients with mutated FLT3 AML (data from 15 of 20 patients studied, n = 1 for data points without SE bar).